Mixed mineral dust pneumoconiosis

Summary

Mixed mineral dust pneumoconiosis (MONDO:0001000) is a disease. A subtype of pneumoconiosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mixed mineral dust pneumoconiosis
Mondo ID	MONDO:0001000
DOID	DOID:10319
NCIT	C27559
SNOMED CT	233759002
UMLS	C0340184
MedGen	137937
GARD	0022861
Is cancer (heuristic)	no

Also known as: mineral duct pneumoconiosis · mineral dust pneumoconiosis · mixed mineral dust pneumoconiosis · pneumoconiosis from mineral dust

Disease family

This is a subtype of pneumoconiosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › interstitial lung disease › pneumoconiosis › mixed mineral dust pneumoconiosis

Related subtypes (13): baritosis, pneumoconiosis due to talc, slate pneumoconiosis, Caplan syndrome, silicosis, anthracosilicosis, anthracosis, byssinosis, pulmonary hemosiderosis, chronic beryllium disease, asbestosis, mixed dust pneumoconiosis, graphite pneumoconiosis

Subtypes (1): kaolin pneumoconiosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.